Compass Therapeutics (CMPX) Return on Sales (2024 - 2025)
Compass Therapeutics recorded quarterly Return on Sales of 0.78% in Q2 2025, down 26.27% quarter-over-quarter from 0.62% in Q4 2024, and down 63.0% year-over-year from 2.11% in Q2 2024.
Compass Therapeutics' Return on Sales history runs 2 years deep, the most recent figure standing at 0.78% for Q2 2025.
- In Q2 2025, Return on Sales fell 63.0% year-over-year to 0.78%; the TTM figure through Jun 2025 stood at 0.78% (down 23.0% YoY), while the FY2024 annual figure was 0.67%, changed N/A from the prior year.
- Return on Sales came in at 0.78% for Q2 2025 at Compass Therapeutics, down from 0.62% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 0.15% in Q2 2024 to a low of 0.78% in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.00% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.00% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 0.00% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.00% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.00% |
| 10 | Compass Therapeutics | 418.47 Mn | 223.78 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -0.78% |
| Dec 31, 2024 | -0.62% |
| Sep 30, 2024 | -0.58% |
| Jun 30, 2024 | -0.15% |